Cancer staging—cancer staging scheme source, code N[N]
Data Element Attributes
Identifying and definitional attributes | |
Metadata item type: | Data Element |
|---|---|
| Short name: | Staging scheme source |
| METEOR identifier: | 720534 |
| Registration status: | Health, Standard 16/01/2020 |
| Definition: | The reference which describes in detail the methods of staging and the definitions for the classification system used in determining the extent of cancer, as represented by a code. |
| Data Element Concept: | Cancer staging—cancer staging scheme source |
| Value Domain: | Cancer staging scheme source code N[N] |
Value domain attributes | ||
Representational attributes | ||
| Representation class: | Code | |
|---|---|---|
| Data type: | Number | |
| Format: | N[N] | |
| Maximum character length: | 2 | |
| Value | Meaning | |
| Permissible values: | 1 | TNM Classification of Malignant Tumours (UICC) |
| 2 | Durie & Salmon for multiple myeloma staging | |
| 3 | French-American-British (FAB) for leukaemia classification | |
| 4 | Australian Clinico-Pathological Staging (ACPS) System for colorectal cancer | |
| 5 | International Federation of Gynecologists & Obstetricians (FIGO) for gynaecological cancers | |
| 6 | Dukes/Modified Dukes for colorectal cancer | |
| 7 | Ann Arbor staging system for lymphomas | |
| 8 | Binet Staging Classification for chronic lymphocytic leukaemia | |
| 9 | Rai staging system for chronic lymphocytic leukaemia | |
| 10 | Chronic Myeloid Leukaemia (CML) staging system | |
| 11 | International Staging System (ISS) for myeloma | |
| 12 | American Joint Committee on Cancer (AJCC) Cancer Staging Manual | |
| 96 | Other reference | |
| Supplementary values: | 97 | Not applicable |
| 98 | Unknown | |
| 99 | Not stated/inadequately described | |
Collection and usage attributes | |
| Guide for use: | CODE 10 Chronic Myeloid Leukaemia (CML) staging system Criteria for diagnosing the transition from the chronic phase into the accelerated phase in patients with Chronic Myeloid Leukaemia (CML) is variable. The WHO criteria (Vardiman et al. 2002) are perhaps the most widely used and are recommended. |
|---|---|
Source and reference attributes | |
| Reference documents: | American Joint Committee on Cancer 2016. AJCC Cancer Staging Manual, 8th edition. New York: Springer Astler VB & Coller FA 1954. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139:846 Cancer Council Australia Colorectal Cancer Guidelines Working Party2017. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. Sydney: The Cancer Council Australia Benedet JL & Pecorelli S 2000. Staging classifications and clinical practice guidelines of gynaecologic cancers. FIGO Committee on Gynaecologic Oncology Bennett JM et al. 1985. Proposed revised criteria for the classification of acute myeloid leukaemia. French-American-British (FAB) co-operative group. Ann Intern Med 103(4):620-625 Binet JL et al. 1981. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198-206 Binet JL et al. 1981. Proposals for a revised staging system. Br J Haematol 48:365-7 Carbone PA, Kaplan HS, Musshoff K, Smithers, DW, Tubiana M 1971. Report of the committee on Hodgkin’s disease staging classification. Cancer Research 31:1860-1861 Davis NC & Newland RC 1983. The reporting of colorectal cancer: the Australian Clinico-pathological Staging (ACPS) System. Med J Aust 1(6):282 Dukes CE 1932. The classification of cancer of the rectum. J Pathol Bacteriol 35:323 Durie BG & Salmon SE 1975. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36(3):842-54 Greipp PR et al. 2005. International Staging System for Multiple Myeloma. J Clin Oncol 23(15):3412-20 International Myeloma Working Group 2003. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749-757 Lister TA et al. 1989. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7(11):1630-6 Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN 1975. Clinical staging of chronic lymphocytic leukaemia. Blood 46(2):219-34 Rosenberg SA 1977. Validity of the Ann Arbor staging classification for the non-Hodgkin’s lymphomas. Cancer Treat Rev 61:1023-27 Sobin LH, Gospodarowicz MK, Wittekind C (Editors) 2016. Union for International Cancer Control (UICC): TNM Classification of Malignant Tumours. 8th ed. Hoboken, NJ: Wiley-Blackwell Vardiman JW, Harris NL, Brunning RD 2002. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100(7):2292-2302 |
|---|---|
Data element attributes | |
Collection and usage attributes | |
| Guide for use: | It is recommended that the TNM Classification of Malignant Tumours (Union for International Cancer Control (UICC)) or the American Joint Committee on Cancer (AJCC) Cancer Staging Manual be used whenever it is applicable. The classifications published in the AJCC Cancer Staging Manual are identical to the TNM classifications of the UICC. TNM is not applicable to all tumour sites. Staging is of limited use in some cancers, for example, haematological malignancies. In these cases use the most appropriate classification system. The Cancer Council Australia Clinical practice guidelines for the prevention, early detection and management of colorectal cancer (2017) support the use of the Australian Clinico-Pathological Staging (ACPS) System. They recommend that both TNM and ACPS staging data be recorded to enable national and international comparisons. A table of correspondences between ACPS and TNM classifications is available. The current edition of each staging scheme should be used. |
|---|---|
| Comments: | Collected to identify which classification system is used to determine the extent of cancer at the time of diagnosis. Cancer stage is an important determinant of treatment and prognosis, and is used to evaluate new treatments and analyse outcomes. Survival analysis is adjusted by stage at diagnosis and distribution of cancer cases by type and stage. |
Source and reference attributes | |
| Submitting organisation: | Cancer Australia Australian Institute of Health and Welfare |
| Origin: | Union for International Cancer Control (UICC) FAB (French-American-British) Group NSW Health Department National Health & Medical Research Council Clinical Oncological Society of Australia Australian Cancer Network |
Relational attributes | |
| Related metadata references: | Supersedes Cancer staging—cancer staging scheme source, code N[N] Health, Superseded 16/01/2020 See also Cancer staging—cancer staging scheme source edition number, code N[N] Health, Standard 07/12/2011 See also Person with cancer—extent of primary cancer, stage grouping other, code X[XXXXX] Health, Standard 07/12/2011 |
| Implementation in Data Set Specifications: | |